Arena Pharmaceuticals Announces First Subject Dosed in ELEVATE UC 52 Global Phase 3 Trial Evaluating Etrasimod in Ulcerative Colitis

Mon June 17, 2019 8:30 AM|PR Newswire|About: ARNA

• - ELEVATE UC clinical trial sites continue to initiate

PR Newswire

SAN DIEGO, June 17, 2019 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA) (Nasdaq: ARNA)

 Ironwood and Allergan Report Positive Topline Data from Phase IIIb Trial of LINZESS® (linaclotide) in Adults with Irritable Bowel Syndrome with Constipation (IBS-C)

Tue June 18, 2019 4:05 PM|Business Wire|About: AGN, IRWD 

FDA Approves Amgen And Allergan's KANJINTI™ (trastuzumab-anns), A Biosimilar To Herceptin® (trastuzumab)

• Thu June 13, 2019 7:13 PM|PR Newswire|About: AGN, AMGN
• Third FDA Approval From Amgen's Biosimilars Portfolio

PR Newswire

THOUSAND OAKS, Calif., June 13, 2019 /PRNewswire/ -- Amgen (AMGN) and Allergan plc (AGN)

 BeiGene and SpringWorks Therapeutics Announce the Formation of MapKure to Develop BGB-3245, an Investigational, Selective Next-Generation RAF Kinase Inhibitor

Tue June 18, 2019 7:00 AM|GlobeNewswire|About: BGNE

CAMBRIDGE, Mass. and BEIJING, China and STAMFORD, Conn., June 18, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (BGNE)

 Gilead and Nurix Establish Strategic Collaboration to Develop Novel Therapies for Cancer and Other Diseases

Wed June 19, 2019 8:30 AM|GlobeNewswire|About: GILDGlobeNewswire

FOSTER CITY, Calif. and SAN FRANCISCO, June 19, 2019 (GLOBE NEWSWIRE) -- Gilead Sciences, Inc. (GILD) and Nurix Therapeutics, Inc

 Amgen And The Institute For Protein Design (IPD) At University Of Washington Announce Unique Strategic Research Partnership

Wed June 19, 2019 4:00 PM|PR Newswire|About: AMGNPR Newswire

THOUSAND OAKS, Calif. and SEATTLE, June 19, 2019 /PRNewswire/ -- Amgen (AMGN) and the University of Washington's Institute for Protein Design (IPD)

 https://www.prnewswire.com/news-releases/amgen-and-the-institute-for-protein-design-ipd-at-university-of-washington-announce-unique-strategic-research-partnership-300871544.html 

Sorrento Therapeutics Updates Positive Results of Phase 1b Resiniferatoxin (RTX) in Knee Osteoarthritis Pain Trial

Wed June 19, 2019 7:00 AM|GlobeNewswire|About: SRNE 

 Regeneron CD20xCD3 Bispecific REGN1979 Shows Positive Results in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma, including in CAR-T Failures

Fri June 14, 2019 7:00 AM|PR Newswire|About: REGN

TARRYTOWN, N.Y., June 14, 2019 /PRNewswire/ 

 MorphoSys's Licensee Janssen Announces Top-line Phase 3 Results for Guselkumab (Tremfya(R)) in Adults with Active Psoriatic Arthritis

Fri June 14, 2019 8:20 AM|Accesswire|About: JNJ, MOR, MPSYY

PLANEGG and MUNICH, GERMANY / ACCESSWIRE / June 14, 2019 / MorphoSys AG (MPSYF) (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; Nasdaq: MOR) 

 Bausch + Lomb ULTRA® Multifocal for Astigmatism Contact Lenses Now Available In the United States

Wed June 19, 2019 7:00 AM|PR Newswire|About: BHC

New Lens is the Most Advanced Soft Contact Lens Design in Bausch + Lomb History

Only Multifocal Toric Lens that Offers Eye Care Professionals a Convenient Same-Day Fit to Address Patients with Astigmatism and Presbyopia

BRIDGEWATER, N.J., June 19, 2019 /PRNewswire/ -- Bausch + Lomb, a leading global eye health company and wholly owned subsidiary of Bausch Health Companies Inc. (BHC)

 AstraZeneca and Merck’s LYNPARZA® (olaparib) Approved in Japan as First-Line Maintenance Therapy in Patients with BRCA-Mutated Advanced Ovarian Cancer

Wed June 19, 2019 6:45 AM|Business Wire|About: MRK

LYNPARZA is the Only PARP Inhibitor Approved in Japan

KENILWORTH, N.J.--(BUSINESS WIRE)-- AstraZeneca and Merck (MRK)

Lilly Presents Positive Results for Taltz® (ixekizumab) vs. Humira® (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis at the European Congress of Rheumatology

Fri June 14, 2019 3:24 PM|Canada Newswire|About: LLY

TORONTO, June 14, 2019 /CNW/ - Eli Lilly and Company (LLY)

LYNPARZA® (olaparib) Approved in the EU for Use as First-Line Maintenance Therapy in Patients With BRCA-Mutated Advanced Ovarian Cancer

Tue June 18, 2019 6:30 AM|Business Wire|About: MRK

AstraZeneca and Merck’s LYNPARZA Reduced the Risk of Disease Progression or Death by 70% Compared to Placebo Following Response to Platinum-Based Chemotherapy in Phase 3 SOLO-1 Trial

LYNPARZA is the Only PARP Inhibitor Approved in the EU for This Indication

KENILWORTH, N.J.--(BUSINESS WIRE)-- AstraZeneca and Merck (MRK), 

BioMarin Announces New England Journal of Medicine Publishes Vosoritide Phase 2 Study Showing Sustained Annualized Growth Up to 42 Months in Children with Achondroplasia

Tue June 18, 2019 8:31 AM|PR Newswire|About: BMRNPR Newswire

SAN RAFAEL, Calif., June 18, 2019 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (BMRN)

FDA approves Novo Nordisk's Type 2 diabetes drug for young patients

Jun. 17, 2019 6:03 PM ET|About: Novo Nordisk A/S (NVO)|By: Carl Surran, SA News Editor 

BeiGene Announces Updated Results from a Pivotal Phase 2 Study of Tislelizumab in Chinese Patients with Relapsed or Refractory Classical Hodgkin Lymphoma at the 24th Congress of the European Hematology Association (EHA)

Fri June 14, 2019 2:30 AM|GlobeNewswire|About: BGNEGlobeNewswire

CAMBRIDGE, Mass. and BEIJING, China, June 14, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (BGNE)

bluebird bio Presents Long-Term Efficacy and Safety Data from Clinical Studies of LentiGlobin® Gene Therapy for Transfusion-Dependent β-Thalassemia (TDT) at 24th European Hematology Association (EHA) Congress

Fri June 14, 2019 5:31 AM|Business Wire|About: BLUE 

Pfizer to Acquire Array BioPharma

Mon June 17, 2019 6:54 AM|PR Newswire|About: ARRY, PFE 

 PR Newswire

NEW YORK, and BOULDER, Colo., June 17, 2019 /PRNewswire/ -- Pfizer Inc (PFE) and Array BioPharma Inc. (ARRY) 

AstraZeneca's Lokelma helped improve potassium levels in dialysis patients

Jun. 14, 2019 8:09 AM ET|About: AstraZeneca PLC (AZN)|By: Liz Kiesche, SA News Edito 

 New Mechanistic Study Explores the Relationship Between a Key Genetic Marker and Clinical Efficacy of ORENCIA® (abatacept) or adalimumab in Moderate-to-Severe Early Rheumatoid Arthritis Patients

Thu June 13, 2019 4:30 PM|Business Wire|About: BMY 

CALQUENCE® (acalabrutinib) Significantly Prolonged the Time Patients Lived without Disease Progression in Relapsed or Refractory  

Chronic Lymphocytic Leukemia

Sat June 15, 2019 7:00 AM|Business Wire|About: AZN

An encouraging 88% of patients on CALQUENCE remained free of disease progression after 12 months, vs. 68% of patients on rituximab combined with idelalisib or bendamustine

WILMINGTON, Del.--(BUSINESS WIRE)--

Amgen Announces BLINCYTO® (blinatumomab) Five-Year Overall Survival Data At EHA 2019

• Sun June 16, 2019 2:00 AM|PR Newswire|About: AMGN
• More Than Half of Patients who Achieved an MRD-Negative Complete Response Still Alive at Five Years
• Only CD19-Targeted Immuno-oncology Therapy With Five-Year Survival Data

PR Newswire

THOUSAND OAKS, Calif., June 15, 2019 /PRNewswire/ -- Amgen (AMGN) 

 ULTOMIRIS® (ravulizumab) Receives Marketing Authorization from Japan’s Ministry of Health, Labour and Welfare (MHLW) for the Treatment of Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Tue June 18, 2019 6:30 AM|Business Wire|About: ALXN 

FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as Monotherapy for Patients with Metastatic Small Cell Lung Cancer (SCLC) with Disease Progression on or After Platinum-Based Chemotherapy and at Least One Other Prior Line of Therapy

Tue June 18, 2019 6:45 AM|Business Wire|About: MRK

Marks First Approval for KEYTRUDA in SCLC

KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (MRK)

 Neurocrine Biosciences to Present Data on INGREZZA® (valbenazine) and Opicapone at the 2019 World Congress on Parkinson's Disease and Related Disorders

Tue June 11, 2019 4:01 PM|PR Newswire|About: NBIX

- Pooled Analyses of Two Pivotal Studies Showed Opicapone Reduced OFF Time and Was Generally Well Tolerated in More than 500 Patients with Parkinson's Disease and Motor Fluctuations

PR Newswire

SAN DIEGO, June 11, 2019 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NBIX)

 https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-data-on-ingrezza-valbenazine-and-opicapone-at-the-2019-world-congress-on-parkinsons-disease-and-related-disorders-300865804.html 

FDA Grants Priority Review to Genentech’s Rituxan (Rituximab) in Children with Two Rare Blood Vessel Disorders

Wed June 12, 2019 1:00 AM|Business Wire|About: RHHBY

• There are currently no FDA approved treatments for children living with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA)
• The PePRS study is the first global trial of Rituxan in pediatric patients with GPA or MPA
• Rituxan in combination with glucocorticoids is the only FDA-approved therapy for adults with these two rare forms of vasculitis
• If approved, this would be the first pediatric indication for Rituxan

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY)

BeiGene Announces Clinical Data on Zanubrutinib to Be Presented at the 15th International Conference on Malignant Lymphoma (ICML)

Wed June 12, 2019 4:00 AM|GlobeNewswire|About: BGNEGlobeNewswire

CAMBRIDGE, Mass. and BEIJING, China, June 12, 2019 (GLOBE NEWSWIRE) -- BeiGene, Ltd. (BGNE)

Varian Medical Systems Presents Latest Innovations in Radiotherapy at DEGRO 25

Wed June 12, 2019 4:00 AM|PR Newswire|About: VAR

MÜNSTER, Germany, June 12, 2019 /PRNewswire/ -- Varian (VSEA) (NYSE: VAR)

Alkermes Advances ALKS 4230 into Monotherapy Expansion Phase of ARTISTRY-1 in Patients With Renal Cell Carcinoma or Melanoma

Wed June 12, 2019 7:00 AM|PR Newswire|About: ALKS 

 PR Newswire

DUBLIN, June 12, 2019 /PRNewswire/ -- Alkermes plc (ALKS) (Nasdaq: ALKS) 

 https://www.prnewswire.com/news-releases/alkermes-advances-alks-4230-into-monotherapy-expansion-phase-of-artistry-1-in-patients-with-renal-cell-carcinoma-or-melanoma-300866051.html 

 http://www.alkermes.com/ 

 Oral semaglutide demonstrated cardiovascular safety in people with type 2 diabetes and established cardiovascular disease or high cardiovascular risk in PIONEER 6 trial

SAN FRANCISCO, June 11, 2019 /PRNewswire/

 Array BioPharma (ARRY) Investor Presentation - Slideshow

Jun. 11, 2019 3:49 PM ET | About: Array BioPharma Inc. (ARRY) 

 June 11, 2019

New Two-Year Data at the 24th World Congress of Dermatology Shows SKYRIZI™ (risankizumab) Maintains Complete Skin Clearance

 NORTH CHICAGO, Ill., June 11, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), 

 INVOKANA® (canagliflozin) Significantly Reduced Major Cardiovascular Events and Kidney Failure in Patients with Type 2 Diabetes and Chronic Kidney Disease in New CREDENCE Analysis 

 SAN FRANCISCO, June 11, 2019 – The Janssen Pharmaceutical Companies of Johnson & Johnson 

Agilent Companion Diagnostic Gains Expanded FDA Approval in Head and Neck Squamous Cell Carcinoma (HNSCC)

Tue June 11, 2019 7:56 AM|Business Wire|About: A

PD-L1 IHC 22C3 pharmDx can now be used as an aid to identify HNSCC patients for treatment with KEYTRUDA® (pembrolizumab)

SANTA CLARA, Calif.--(BUSINESS WIRE)-- Agilent Technologies Inc. (A) 

 https://www.businesswire.com/news/home/20190611005542/en/ 

Varian to Demonstrate New Bravos Afterloader System at ABS 2019

Tue June 11, 2019 8:15 AM|PR Newswire|About: VAR

PALO ALTO, Calif., June 11, 2019 /PRNewswire/ -- Varian (VSEA) (NYSE: VAR

 IMBRUVICA® (ibrutinib) Long-Term Data from Two Pivotal Phase 3 Studies at ASCO and EHA Demonstrate Sustained Efficacy and Safety in Patients with Chronic Lymphocytic Leukemia (CLL) 

 CHICAGO and AMSTERDAM, June 3, 2019 – The Janssen Pharmaceutical Companies of Johnson & Johnson  

AbbVie's MAVIRET™ now listed on the Nova Scotia and Manitoba formularies

Mon June 10, 2019 8:00 AM|Canada Newswire|About: ABBV

• MAVIRET is the first and only 8-week, pan-genotypic treatment for patients with chronic hepatitis C virus (HCV) infection without cirrhosis and who are new to treatment.*1
• MAVIRET is the only pan-genotypic treatment approved for use in patients across all stages of chronic kidney disease (CKD).

MONTREAL, June 10, 2019 /CNW/ - AbbVie (ABBV)

 http://www.abbvie.ca/ 

 Positive Feline Clinical Trial Outcome Motivates Sorrento Therapeutics to Accelerate Human IND Filing of Resiniferatoxin (RTX) for Prolonged Non-Opioid Control of Post-Amputation Neuropathic Pain

Mon June 10, 2019 7:00 AM|GlobeNewswire|About: SRNE

SAN DIEGO, June 10, 2019 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (SRNE)

FDA Approves Two New Indications for Merck’s KEYTRUDA® (pembrolizumab)

Tue June 11, 2019 6:45 AM|Business Wire|About: MRK

KEYTRUDA Now Approved for First-Line Treatment of Patients with Metastatic or with Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma as Monotherapy for Patients Whose Tumors Express PD-L1 (CPS ≥1) or in Combination with Platinum and Fluorouracil (FU) Regardless of PD-L1 Expression

KENILWORTH, N.J.--(BUSINESS WIRE)-- Merck (MRK)

 https://www.businesswire.com/news/home/20190611005275/en/ 

FDA Grants Genentech’s Polivy Accelerated Approval for People with Previously Treated Aggressive Lymphoma

Mon June 10, 2019 12:36 PM|Business Wire|About: RHHBY

– New targeted medicine shown to improve clinical outcomes in people with relapsed or refractory diffuse large B-cell lymphoma compared to a commonly used regimen –

– First-in-class antibody-drug conjugate that specifically targets CD79b, a protein expressed in the majority of B-cells –

– Ninth indication with Breakthrough Therapy Designation in Genentech’s hematology portfolio to receive FDA approval –

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY)

 https://www.businesswire.com/news/home/20190610005588/en/ 

Tetraphase Pharmaceuticals Announces New XERAVA™ (eravacycline) Data at the 39th Annual Surgical Infection Society Meeting

Mon June 10, 2019 7:00 AM|Business Wire|About: TTPH

-Study Examines Microbiology and Hospitalization Outcomes Among Complicated Intra-Abdominal Infection Patients-

-Data Underscore XERAVA’s Role as an Empiric Treatment Option for Patients With Complicated Intra-Abdominal Infections-

WATERTOWN, Mass.--(BUSINESS WIRE)-- Tetraphase Pharmaceuticals, Inc. (TTPH) (NASDAQ:TTPH)

 https://www.businesswire.com/news/home/20190610005030/en/ 

 Sesen Bio Announces Successful Pre-BLA Meeting with FDA for Vicinium®

Mon June 10, 2019 7:00 AM|Business Wire|About: SESN

FDA Recommends Accelerated Approval Pathway

FDA Indicated No Additional Clinical Trials Necessary for BLA Submission

Company Expects to Initiate Submission of the BLA in 4Q 2019 Under Rolling Review

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sesen Bio (SESN) (Nasdaq:SESN)

 https://www.businesswire.com/news/home/20190610005190/en/ 

 Veracyte Announces New Publication of Data Demonstrating Real-World Performance of the Afirma GSC in Thyroid Cancer Diagnosis

Mon June 10, 2019 4:15 PM|Business Wire|About: VCYT

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc (VCYT)

 http://www.afirma.com/patients/ 

Detailed findings from CAROLINA® outcome trial support long-term cardiovascular safety profile of Tradjenta®

Mon June 10, 2019 9:30 PM|PR Newswire|About: LL 

• Adults with diabetes treated with Tradjenta experienced fewer events of hypoglycemia and a modest weight reduction compared with glimepiride
• - Detailed results from CAROLINA were presented at the American Diabetes Association's 79th Scientific Sessions

PR Newswire

RIDGEFIELD, Conn. and INDIANAPOLIS, June 10, 2019 /PRNewswire/ -- Boehringer Ingelheim and Eli Lilly and Company (LLY) 

 https://www.tradjenta.com/ 

 https://www.prnewswire.com/news-releases/detailed-findings-from-carolina-outcome-trial-support-long-term-cardiovascular-safety-profile-of-tradjenta-300864614.html 

Lilly to Present 5-Year Sustained Efficacy and Safety Results for Taltz® (ixekizumab) in Patients with Plaque Psoriasis at the World Congress of Dermatology

Tue June 11, 2019 3:00 AM|PR Newswire|About: LLY

INDIANAPOLIS, June 11, 2019 /PRNewswire/ -- Eli Lilly and Company (LLY) 

 https://www.taltz.com/ 

Genentech’s Gazyva (Obinutuzumab) Delivers Positive Topline Results for Phase II Lupus Nephritis Study

Tue June 11, 2019 1:00 AM|Business Wire|About: RHHBY

• NOBILITY showed that Gazyva helped more patients achieve a complete renal response when added to standard of care
• The Phase II study met both primary and key secondary endpoints
• There are currently no FDA-approved therapies for lupus nephritis

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY)

 https://www.businesswire.com/news/home/20190610005836/en/ 

New analysis shows cardiorenal risk reductions of Jardiance® are consistent in adults with type 2 diabetes, cardiovascular disease and kidney disease without overt proteinuria

Mon June 10, 2019 1:00 PM|PR Newswire|About: LLYPR Newswire

RIDGEFIELD, Conn. and INDIANAPOLIS, June 10, 2019 /PRNewswire/

 https://www.prnewswire.com/news-releases/new-analysis-shows-cardiorenal-risk-reductions-of-jardiance-are-consistent-in-adults-with-type-2-diabetes-cardiovascular-disease-and-kidney-disease-without-overt-proteinuria-300864270.html 

FARXIGA Study Showed Reduced Progression of Kidney Disease or Renal Death in Patients with Type 2 Diabetes

Mon June 10, 2019 8:00 AM|Business Wire|About: AZN

FARXIGA showed a 47% reduction in the composite of kidney function decline, end-stage renal disease or renal death in a pre-specified analysis from DECLARE-TIMI 58

WILMINGTON, Del.--(BUSINESS WIRE)

 https://www.businesswire.com/news/home/20190610005198/en/ 

 Jun. 8, 2019 5:21 PM ET|About: Amgen Inc. (AMGN), AZN, BMY, CELG, LLY, MRK, PFE

Summary

politicos started the BIOTECH-WARS™ and they are continuing the war.

the BIOTECH-WAR$ led to the vilification of the biotech sector.

the Biotech industry severely miscalculated and underestimated the situation they find themselves in.

 Jun. 5, 2019 4:18 PM ET|About: AbbVie Inc. (ABBV), AMGN, BMRN, CELG, JNJ, LLY, MRK, NVS, PFE, RHHBY

Summary

The perfect BIOTECH$TORM is not over, perhaps it is only in the early stages.

In NJ more taxes coming, more pain, more debt, unfunded liabilities, and in my view a rapid exit of many high-income people from my home state of New Jersey.

Nevertheless, meanwhile and more importantly Biotech Companies continue to make significant product and financial progress irrespective of the negative political environment that only seems to be getting worse.

 Jun. 3, 2019 12:30 PM ET|About: Amgen Inc. (AMGN), AZN, BMY, CELG, GILD, MRK, NVS, RHHBY, SGEN

Summary

The Perfect BIOTECH$TORM is occurring right now, June 2019.

Trade Wars, Legal Battles, Political Battles, all impact to create the Perfect BIOTECHSTORM.

Nevertheless Biotech companies continue to develop wonderful new products every day.

 May 24, 2019 11:56 AM ET|About: Celgene Corporation (CELG), JNJ, LLY, MRK, NVS, Includes: ABBV, ARRY, MDT, PFE

Summary

the BIOTECH WAR$ have expanded to include a new and unexpected target, “wealthy people”.

the victorious party wants to remove all undesirable citizens/unlikely supporters from the state in which they live. Acrimony against biotech companies and now wealthy citizens is where we are at.

Biotech companies are an insufficient sector to the politico’s, and a more expansive “Bad Guy Group” is now needed – i.e., wealthy people, especially if you live in NJ

 May 9, 2019 8:52 AM ET|About: Johnson & Johnson (JNJ), MRK

Summary

the BIOTECH WAR$ may represent a deeper battle going on between the “Socialist” political movement and our current “Capitalistic” economy.

Achieving political power supersedes common sense and support for the biotech business sector becomes non-existent as the sector is politically vilified.

Positive biotech product news seems to have little effect towards improving market valuations.

 Apr. 30, 2019 5:44 PM ET|About: Amgen Inc. (AMGN), JNJ, MRK, Includes: BMY, CELG, NVO, NVS, PFE, RHHBY

Summary

The “Medicare for all” and the “drug pricing” messaging is working for all those who seek political gain.

Biotech, Medtech and the entire Healthcare sector are losing the battles, and the war as investors flee for less politically targeted sectors.

NJ residents see the "P/C", "Middle Class Only"/ Socialism wave coming.

I may need to stop being so publicly supportive of Biotech companies.

 Feb. 20, 2019 11:04 PM ET|Includes: AbbVie Inc. (ABBV), ABT, ALKS, AMGN, CELG, CERC, CLVS, JNJ, LLY, MDT, MRK, NVO, PFE

Summary

A BIOTECH VORTEX™ is occurring across the entire healthcare sector as companies are now Seeking Biotech Partnerships to gain momentum.

Biotech & Biotech Partnerships.

Biotech & Medtech Partnerships.

Biotech & Medtech & Medical Universities Partnerships.

Biotech & Health Systems Partnerships.

  Mar. 6, 2019 8:12 AM ET|Includes: AbbVie Inc. (ABBV), AMGN, AZN, BMY, CELG, JNJ, LLY, MRK, PFE, SRPT

Summary

Sometimes biotech news is wonderful news.

Sometimes biotech news is the best and most upbeat news I read all day.

Sometimes with great effort and much time and money spent biotech news is remarkable news for many people seeking solutions to specific medical conditions and aliments.

The first 2 months of 2019 have been extremely strong for many of my biotech positions.

 Feb. 1, 2019 9:27 PM ET|

6 comments |Includes: Abiomed, Inc. (ABMD), BIIB, ILMN, ISRG, MRK, RHHBY, SRPT, VA 

 Almost every piece of company news I was reading was positive and encouraging during the December 2018 time frame. 

 Feb. 12, 2019 4:16 PM ET|2 comments |About: AbbVie Inc. (ABBV), AZN, BMY, JNJ, MRK, PFE, SNY

Summary

Biotech companies are easy targets as they are on TV with their advertised products on a year-round basis and they are successful and profitable.

If an incumbent senator can successfully attack a successful and profitable biotech company, that is in his home state, then so can everyone else.

Should any politician target any biotech company in their home state, then most likely they will win votes and are more likely to win elections.

I think these hearings will eventually benefit biotech companies as insurance companies and PBM's and other "profiteers" in the healthcare pricing matrix are exposed.

As a biotech investor the upcoming/ongoing congressional hearings on drug pricing (2/26/2019) does have me feeling a bit on edge.   

  Apr. 2, 2019 8:20 PM ET|About: AstraZeneca PLC (AZN), BMY, CELG, Includes: AMRN, JNJ, MRK, NVO, NVS, PFE, RHHBY, SNY

Summary

“TINSTAAFL” = “There is no such thing as a free lunch”.

Princeton NJ/Central Jersey – is for me the best example of a successful BioTECH Zone.

Ireland's Life Sciences sector has grown from very humble beginnings in the 1960s to reach global significance. Collaborative clusters in Pharmaceutical, Biotechnology, Medical Devices and Diagnostics have been a key.

AstraZeneca is spearheading the creation of a new life sciences park, in Wuxi, China, that aims to nurture innovation.

Cambridge, Mass, is one of the best examples of a successful BioTECH Zone.

 Mar. 14, 2018 1:14 PM ET|About: Amgen Inc. (AMGN), AZN, BGNE, CELG, NVS, Includes: ABMD, BMY, LLY, MDT, MRK, NVO

Summary

China Bio-Tech growth is accelerating now.

China needs better healthcare in every province.

China will welcome all bio-technology partnerships.

China is on the verge of major investment changes.

 INDIANAPOLIS, Oct. 4, 2018 /PRNewswire/   

Lilly's Investigational Dual GIP and GLP-1 Receptor Agonist Shows Significant Reduction in HbA1c and Body Weight in People With Type 2 Diabetes

Thu October 4, 2018 6:45 AM|Business Wire|About: MRK

 Merck’s HIV Therapy DELSTRIGO™ (doravirine / lamivudine / tenofovir disoproxil fumarate) Meets Primary Efficacy Endpoint in Phase 3 DRIVE-SHIFT Study Evaluating Switch to DELSTRIGO from Other Antiretroviral Treatment Regimens

 Health Canada OKs AbbVie's elagolix for endometriosis-related pain

Oct. 6, 2018 2:20 PM ET|About: AbbVie Inc. (ABBV)|By: Douglas W. House, SA News Editor  

 Gilead Announces 96-Week Results From Phase 3 Study of Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 in Adults New to HIV Therapy

Wed October 3, 2018 8:30 AM|Business Wire|About: GILD

– Biktarvy Showed High Efficacy and a Demonstrated Tolerability Profile Through 96 Weeks –

 New SPINRAZA® (nusinersen) Data Presented at Annual Congress of the World Muscle Society Demonstrate Benefits in Treating Presymptomatic Infants with Spinal Muscular Atrophy

Sat October 6, 2018 7:30 AM|GlobeNewswire|About: BIIB 

 FDA OKs expanded use for Merck's Gardasil 9 HPV vaccine

Oct. 5, 2018 4:58 PM ET|About: Merck & Co Inc. (MRK)|By: Douglas W. House, SA News Editor 

 Thu September 27, 2018 7:52 PM|PR Newswire|About: LLY

INDIANAPOLIS, Sept. 27, 2018 /PRNewswire/ -- Eli Lilly and Company (LLY) 

Lilly's Emgality™ (galcanezumab-gnlm) Receives U.S. FDA Approval for the Preventive Treatment of Migraine in Adults

  Thu September 27, 2018 5:41 PM|Business Wire|About: PFE 

 NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (PFE) 

U.S. FDA Approves VIZIMPRO® (dacomitinib) for the First-Line Treatment of Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer

 by Nick Paul Taylor | 

Sep 28, 2018 7:33am

 Roche has paid €70 million ($81 million) upfront to buy Tusk Therapeutics. The takeover gives Roche control of an anti-CD25 antibody that depleted levels of regulatory T cells (Tregs) in preclinical tests 

  Sep. 28, 2018 7:07 AM ET|About: Novo Nordisk A/S (NVO)|By: Douglas W. House, SA News Editor 

Novo's once-weekly somapacitan on par with daily Norditropin in mid-stage study

 Thursday, September 20, 2018 - 8:00amEDT

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE)

 PFIZER GRANTED FDA BREAKTHROUGH THERAPY DESIGNATION FOR 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE FOR THE PREVENTION OF INVASIVE DISEASE AND PNEUMONIA IN ADULTS AGED 18 YEARS AND OLDER

 SAN DIEGO, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP)  

Adamis Pharmaceuticals Receives FDA Approval for Its Lower Dose Symjepi Product 

 Novartis (NYSE:NVS) unit Sandoz will commercialize. 

 Sep. 18, 2018 8:24 AM ET|About: AstraZeneca Group plc (AZN)|By: Mamta Mayani, SA News Editor   

AstraZeneca's FASENRA shows safety and sustained efficacy in long-term phase III BORA trial in severe eosinophilic asthma

  September 18, 2018 06:59 AM EDT

PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY

European Medicines Agency Validates Bristol-Myers Squibb’s Application for Empliciti (elotuzumab) Plus Pomalidomide and Low-Dose Dexamethasone in Patients with Multiple Myeloma

   Sep. 18, 2018 7:22 AM ET|By: Douglas W. House, SA News Editor  

The European Medicines Agency (EMA) accepts for review Bristol-Myers Squibb's (NYSE:BMY) marketing application seeking approval for EMPLICITI (elotuzumab), in combination with Celgene's (NASDAQ:CELG) POMALYST (pomalidomide) and low-dose dexamethasone, for the treatment of adult patients with multiple myeloma (MM) 

 DUBLIN - September 18, 2018 - Medtronic plc (NYSE:MDT)  

(GLOBE NEWSWIRE via COMTEX) --Medtronic Receives FDA Approval for Revised TAVR Labeling and Begins Investigational Study of Low Risk Patients with Bicuspid Valves 

 Sep. 17, 2018 7:25 AM ET|About: AstraZeneca Group plc (AZN)|By: Douglas W. House, SA News Editor 

 AstraZeneca's PT010 shows treatment benefit in late-stage COPD study

 Mon September 24, 2018 9:00 PM|PR Newswire|About: AMGN 

 BLINCYTO® (blinatumomab) Approved In Japan For The Treatment Of Relapsed Or Refractory B-cell Acute Lymphoblastic Leukemia

Sep. 14, 2018 4:50 PM ET  | About: Roche Holding Ltd ADR (RHHBY), RHHBF 

Roche Holding's (RHHBY) Virtual Late Stage Pipeline Event 2018 - Slideshow

 Sat September 15, 2018 2:00 AM|Business Wire|About: PFE

NEW YORK--(BUSINESS WIRE)-- 

Pfizer Inc. (PFE) today announced results from its Phase 2a study of PF-06651600, an oral Janus kinase (JAK) 3 inhibitor, and PF-06700841, a tyrosine kinase (TYK) 2/JAK1 inhibitor, 

  by john carroll — on September 14, 2018 08:37 AM EDT 

 According to the Albany Times-Union, Regeneron $REGN had already told officials last month that they were expanding their plans for manufacturing, office and lab space in Rensselaer, boosting their initial hiring plans from 1,100 to 1,500 while blueprinting an extra 300,000 square feet of space for the complex. 

  
Zach Hartman  Sep. 14, 2018 8:00 AM ET 

Merck Tightening Its Grips On Front-Line Lung Cancer

  By The ASCO Post
Posted: 9/13/2018 2:20:30 PM
Last Updated: 9/13/2018 5:04:27 PM 

(FDA) today approved moxetumomab pasudotox-tdfk (Lumoxiti) injection for intravenous use for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) 

  TARRYTOWN, N.Y. and PARIS, Sept. 15, 2018 /PRNewswire/ 

Positive Phase 3 Results Presented for Dupixent® (dupilumab) Show Significant Improvement on Multiple Measures of Disease Severity in Adolescents with Moderate-to-Severe Atopic Dermatitis TARRYTOWN, N.Y. and PARIS, Sept. 15, 2018 /PRNewswire/